Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

765 ARTÍCULOS , VIENDO DEL 616 AL 630

An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's disease

Lizama BN, North HA, Pandey K, Williams C, Duong D, Cho E, Di Caro V, Ping L, Blennow K, Zetterberg H, Lah J, Levey AI, Grundman M, Caggiano AO, Seyfried NT, Hamby ME.

Neurobiol Dis. 2024 Sep;199:106575. doi: 10.1016/j.nbd.2024.106575. Epub 2024 Jun 22.

Alzheimer's disease approaches - Focusing on pathology, biomarkers and clinical trial candidates

Hroudová J, Fišar Z.

Prog Neuropsychopharmacol Biol Psychiatry. 2024 Aug 30;134:111069. doi: 10.1016/j.pnpbp.2024.111069. Epub 2024 Jun 23.

A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's Disease

Galasko D, Farlow MR, Lucey BP, Honig LS, Elbert D, Bateman R, Momper J, Thomas RG, Rissman RA, Pa J, Aslanyan V, Balasubramanian A, West T, Maccecchini M, Feldman HH.

Alzheimers Res Ther. 2024 Jul 5;16(1):151. doi: 10.1186/s13195-024-01490-z.

Exercise to Counteract Alzheimer's Disease: What Do Fluid Biomarkers Say?

Bonanni R, Cariati I, Cifelli P, Frank C, Annino G, Tancredi V, D'Arcangelo G.

Int J Mol Sci. 2024 Jun 25;25(13):6951. doi: 10.3390/ijms25136951.

Novel Blood-Based Biomarkers and Disease Modifying Therapies for Alzheimer's Disease. Are We Ready for the New Era?

Korologou-Linden R, Kalsi J, Kafetsouli D, Olawale A, Iwata A, Wingfield D, Mummery D, Hayhoe B, Robinson O, Majeed A, Middleton LT.

J Prev Alzheimers Dis. 2024;11(4):897-902. doi: 10.14283/jpad.2024.83.

Alzheimer's disease: from early pathogenesis to novel therapeutic approaches

Prajapati SK, Pathak A, Samaiya PK.

Metab Brain Dis. 2024 Aug;39(6):1231-1254. doi: 10.1007/s11011-024-01389-6. Epub 2024 Jul 24.

A phase 2, open-label study of anti-inflammatory NE3107 in patients with dementias

Haroon J, Jordan K, Mahdavi K, Rindner E, Becerra S, Surya JR, Zielinski M, Venkatraman V, Goodenowe D, Hofmeister K, Zhang J, Ahlem C, Reading C, Palumbo J, Pourat B, Kuhn T, Jordan S.

Medicine (Baltimore). 2024 Jul 26;103(30):e39027. doi: 10.1097/MD.0000000000039027.

Tracking neuroinflammatory biomarkers in Alzheimer's disease: a strategy for individualized therapeutic approaches?

Lista S, Imbimbo BP, Grasso M, Fidilio A, Emanuele E, Minoretti P, López-Ortiz S, Martín-Hernández J, Gabelle A, Caruso G, Malaguti M, Melchiorri D, Santos-Lozano A, Imbimbo C, Heneka MT, Caraci F.

J Neuroinflammation. 2024 Jul 30;21(1):187. doi: 10.1186/s12974-024-03163-y.

Association between treatment with sacubitril/valsartan and the risk of Alzheimer's disease: a clinical update

Garnier-Crussard A.

Alzheimers Res Ther. 2024 Aug 1;16(1):177. doi: 10.1186/s13195-024-01547-z.

Transcranial blood-brain barrier opening in Alzheimer's disease patients using a portable focused ultrasound system with real-time 2-D cavitation mapping

Bae S, Liu K, Pouliopoulos AN, Ji R, Jiménez-Gambín S, Yousefian O, Kline-Schoder AR, Batts AJ, Tsitsos FN, Kokossis D, Mintz A, Honig LS, Konofagou EE.

Theranostics. 2024 Jul 22;14(11):4519-4535. doi: 10.7150/thno.94206. eCollection 2024.

Updates in Alzheimer's disease: from basic research to diagnosis and therapies

Liu E, Zhang Y, Wang JZ.

Transl Neurodegener. 2024 Sep 4;13(1):45. doi: 10.1186/s40035-024-00432-x.

Deciphering the role of miRNAs in Alzheimer's disease: Predictive targeting and pathway modulation - A systematic review

Sharma M, Pal P, Gupta SK.

Ageing Res Rev. 2024 Nov;101:102483. doi: 10.1016/j.arr.2024.102483. Epub 2024 Sep 3.

Breaking Barriers in Alzheimer's Disease: the Role of Advanced Drug Delivery Systems

Shekho D, Mishra R, Kamal R, Bhatia R, Awasthi A.

AAPS PharmSciTech. 2024 Sep 5;25(7):207. doi: 10.1208/s12249-024-02923-6.

Pathways to personalized medicine-Embracing heterogeneity for progress in clinical therapeutics research in Alzheimer's disease

Arnold SE, Hyman BT, Betensky RA, Dodge HH.

Alzheimers Dement. 2024 Oct;20(10):7384-7394. doi: 10.1002/alz.14063. Epub 2024 Sep 6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias